Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cantargia AB ( (SE:CANTA) ) has shared an update.
Cantargia AB announced preclinical data showing that targeting IL1RAP can effectively counteract tumor-induced systemic immune suppression, potentially enhancing cancer treatment outcomes. These findings, published in Cancer Discovery, highlight nadunolimab’s ability to reduce immunosuppressive myeloid cells, suggesting significant implications for improving immunotherapy responses in cancer patients.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. It has established a platform based on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s oncology program includes the antibody nadunolimab (CAN04), primarily studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. The company also has a second development program, CAN10, targeting autoimmune and inflammatory diseases.
YTD Price Performance: -2.61%
Average Trading Volume: 2,500
Technical Sentiment Signal: Buy
Current Market Cap: €36.77M
For a thorough assessment of CANTA stock, go to TipRanks’ Stock Analysis page.